Skip to main content

Table 3 Clinical characteristics of patients who have survived over 5 years

From: Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?

Characteristics

All

EGFR-Mutated

ALK-Rearranged

N = 46

%

N = 37

%

N = 9

%

Age

 Median (range), years

62 (35–80)

64 (50–80)

51 (35–74)

Sex

 Male

19

41.3

14

37.8

5

55.5

 Female

27

58.7

23

62.1

4

44.4

Smoking status

 Never-smoker

20

43.5

16

43.2

4

44.4

 Current or former smoker

23

50

18

48.6

5

55.5

 Unknown

3

6.5

3

8.1

0

0

Pack-years, median(range)

32(2–114)

32(2–114)

29.5(13–48)

ECOG performance status

 0

33

71.7

27

72.9

6

66.6

 1

10

21.7

8

21.6

2

22.2

 2

0

0

0

0

0

0

  > 2

2

4.3

1

2.7

1

11.1

 Unknown

1

2.1

1

2.7

0

0

Tumor histology

 Adenocarcinoma

42

91.3

34

91.8

8

88.8

 NSCLC, NOS

1

2.1

0

0

1

11.1

 Unknown

3

6.5

3

8.1

0

0

Stage

 Relapse

25

54.3

22

59.4

3

33.3

 III

3

6.5

2

5.4

1

11.1

 IV

18

39.1

13

35.1

5

55.5

Presence of extrathoracic metastases

 Yes

13

28.2

9

24.3

4

44.4

 No

33

71.1

28

75.6

5

55.5

Presence of brain metastases

 Yes

5

10.8

2

5.4

3

33.3

 No

41

89.1

35

94.5

6

66.6